Escitalopram in seasonal affective disorder: Results of an open trial

Pharmacopsychiatry

Volumn 40, Issue 1, 2007, Pages 20-24

  Pjrek, E ^a   Winkler, D ^a   Stastny, J ^a   Praschak Rieder, N ^a   Willelt, M ^a   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; HAMILTON SCALE; HEADACHE; HUMAN; LIBIDO DISORDER; NAUSEA; PRIORITY JOURNAL; REMISSION; SEASONAL AFFECTIVE DISORDER; SEASONAL VARIATION; SELF EVALUATION; SOCIAL ADAPTATION; VERTIGO;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEASONAL AFFECTIVE DISORDER;

EID: 34147156701     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-958718     Document Type: Article

References (45)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. 4th edition, text revision (DSM-IV-TR) Washington, DC: American Psychiatric Press, 2000
2. Bech P: Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs 2005; 19: 313-324
3. Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O et al: The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981; 63: 290-299
4. Bech P, Andersen HF, Wade A: Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 2006; 39: 128-134
5. Bosc M, Dubini A, Polin V: Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 1997; 7 (Suppl 1): 57-70 ; discussion 71-73
6. Brambilla P, Cipriani A, Hotopf M, Barbui C: Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry 2005; 38: 69-77
7. Bundesgesetzblatt für die Republik Österreich. Bundesgesetz vom 2. März 1983 über die Herstellung und das Inverkehrbringen von Arzneimitteln (Arzneimittelgesetz). BGBl. Nt. 185/1983
8. Burke WJ, Gergel I, Bose A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-336
9. Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005; 15: 193-198
10. Ferguson JM: SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001; 3: 22-27
11. First MB, Spitzer RL, Gibbon M, Williams JB: Structured clinical interview for DSM-IV axis I disorders - patient edition. SCID-I/P, version 2.0. New York, NY: New York State Psychiatric Institute, Biometric Research Department, 1996
12. Goodman WK, Bose A, Wang Q: Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005; 87: 161-167
13. Guy W: ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976
14. Kasper S: Jahreszeit und Befindlichkeit in der Allgemeinbevölkerung.Eine Mehrebenenuntersuchung zur Epidemiologic, Biologie und therapeutischen Beeinflußbarkeit (Lichttherapie) saisonaler Befindlichkeitsschwankungen. Monographien aus dem Gesamtgebiet der Psychiatrie, Bd. 66. Berlin, Heidelberg, New York, Tokyo: Springer, 1991
15. Kasper S, Rogers LBS, Yancey A, Schulz PM, Skwerer RG, Rosenthal NE: Phototherapy in individuals with and without subsyndromal seasonal affective disorder. Arch Gen Psychiatry 1989; 46: 837-844
16. Kasper S, Spadone C, Verpillat P, Angst J: Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006; 21: 105-110
17. Kasper S, Stein DJ, Loft H, Nil R: Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186: 222-226
18. Kennedy SH, Andersen HF, Lam RW: Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122-131
19. Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R et al: Multiple Dose Administration of Escitalopram Resulted in a Higher Serotonin Transporter Occupancy than Citalopram: A [I123]ADAM SPECT Study in Healthy Volunteers. Biol Psychiatry 2006; 59 (Suppl 1): 246
20. Lam RW, Andersen HF: The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006; 39: 180-184
21. Lam RW, Gorman CP, Michalon M, Steiner M, Levitt AJ, Corral MR et al: Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995; 152: 1765-1770
22. Lam RW, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Michalak EE et al: The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 2006; 163: 805-812
23. Lepola UM, Loft H, Reines EH: Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211-217
24. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patietns. Acta Psychiatr Scand 1987; 76 (Suppl 334): 1-100
25. Llorca PM, Azorin JM, Despiegel N, Verpillat P: Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005; 59: 268-275
26. Moscovitch A, Blashko CA, Eagles JM, Darcourt G, Thompson C, Kasper S et al: A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacolgy (Berl) 2004; 171: 390-397
27. Neumeister A, Konstantinidis A, Praschak-Rieder N, Willeit M, Hilger E, Stastny J et al: Monoaminergic function in the pathogenesis of seasonal affective disorder. Int J Neuropsychopharmacol 2001; 4: 409-420
28. O'Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JF: Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1997; 95: 379-384
29. Owens MJ, Knight DL, Nemeroff CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345-350
30. Partonen T, Lonnqvist J: Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 1996; 41: 93-99
31. Pjrek E, Winkler D, Kasper S: Pharmacotherapy of seasonal affective disorder. CNS Spectr 2005; 10: 664-669 ; quiz 672
32. Pjrek E, Winkler D, Stastny J, Konstantinidis A, Heiden A, Kasper S: Bright light therapy in seasonal affective disorder - does it suffice? Eur Neuropsychopharmacol 2004; 14: 347-351
33. Rosenthal NE, Bradt GH, Wehr TA: Seasonal Pattern Assessment Questionnaire. Washington, DC: National Institute of Mental Health, 1987
34. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y et al: Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 1984; 41: 72-80
35. Ruhrmann S, Kasper S, Hawellek B, Martinez B, Hoflich G, Nickelsen T et al: Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 1998; 28: 923-933
36. Rush AJ, Bose A: Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005; 21: 26-32
37. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C: Escitalopram versus citalopram: the sutptising role of the R-enantiomer. Psychopharmacology 2004; 174: 163-176
38. SPSS Inc. SPSS 12.0 for Windows. Release 12.0. Chicago, IL, USA; 1989-2003
39. Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64: 1322-1327
40. Wade A, Michael Lemming O, Bang Hedegaard K: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102
41. Weissman MM, Olfson M, Gameroff MJ, Feder A, Fuentes M: A comparison of three scales for assessing social functioning in primary care. Am J Psychiatry 2001; 158: 460-466
42. Williams JBW, Link MJ, Rosenthal NE, Amira L, Terman M: Structured Interview Guide for the Hamilton Depression Rating Scale - Seasonal Affective Disorder Version, 2002 rev. New York, NY: New York State Psychiatric Institute, 2002
43. Winkler D, Pjrek E, Iwaki R, Kasper S: The treatment of seasonal affective disorder. Expert Rev Neurother 2006; 6: 1039-1048
44. Winkler D, Pjrek E, Klein N, Kasper S: Escitalopram in employed people - Results from an observational study in 2378 patients. Psychopharmakotherapie 2006; 13, in press
45. Winkler D, Praschak-Rieder N, Willeit M, Lucht MJ, Hilger E, Konstantinidis A et al: Saisonal abhängige Depression (SAD) in zwei deutschsprachigen Universitätszentren: Bonn, Wien. Seasonal affective disorder in two German-speaking university centers: Clinical and demographic characteristics (German). Nervenarzt 2002; 73: 637-643